InFocus / Evoked Gamma Oscillation (SpectrisTM) as a Potential Therapeutic Intervention for Alzheimer’s Disease
🎤 Dr. Mihály Hajós
🗓️ Monday, November 18
🕧15:00
The event will take place as in person.
📍Location: Istanbul Medipol University Kavacık South Campus / 2nd Floor / Amphi – 206
https://maps.app.goo.gl/fcrzDzeSk8EsEYyF9
Will summarize current findings on SepctrisTM treatment, including preservation of white matter and myelination in AD patients and changes in CSF protein abundance linked to AD-related brain proteome modules, including those involved in myelination, synaptic and neuroimmune functions. The proposed mode of action of this treatment will be also discussed.
📌Participants from outside SABITA must fill in the participation form.
Mihály Hajós
PharmD, PhD
Yale University, School of Medicine
Mihály Hajós, PharmD, PhD is the chief scientific officer at Cognito Therapeutics, and professor adjunct at Yale University School of Medicine. He had both academic and industrial positions, including positions as principal investigator at Pfizer and Biogen, and faculty member at Oxford University Clinical Medicine and Yale University School of Medicine. Dr. Hajos graduated from University of Szeged, Hungary, and received his PhD from University of Gothenburg, Sweden. He published over 130 scientific papers, and he is recognized as a thought leader in translational medicine and CNS biomarkers. Dr. Hajos is particularly interested in designing and developing translational biomarkers for understanding the interaction between abnormal activities of neuronal circuits and pathological mechanisms in Alzheimer’s disease. At Cognito Therapeutics, his main goal is translating experimental findings to clinics, studying evoked gamma oscillation on Alzheimer’s disease pathologies.